Journal List > J Korean Soc Transplant > v.27(3) > 1034398

J Korean Soc Transplant. 2013 Sep;27(3):121-127. Korean.
Published online September 26, 2013.
Copyright © 2013 The Korean Society for Transplantation
Clinical Characteristics and Risk Factors for Renal Cell Carcinoma after Kidney Transplantation
Yun Tae Jung, M.D.,1 Jung Jun Lee, M.D.,1,2 Su Hyung Lee, M.D.,1,2 A-Lan Lee, M.D.,1,2 Kyu Ha Huh, M.D.,1,2 Myoung Soo Kim, M.D.,1,2 Soon Il Kim, M.D.,1,2 Yu Seun Kim, M.D.,1,2 and Dong Jin Joo, M.D.1,2
1Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
2Department of Research Institute for Transplantation, Yonsei University College of Medicine, Seoul, Korea.

Corresponding author (Email: )
Received July 31, 2013; Accepted August 29, 2013.



The occurrence of malignancy following kidney transplantation has been estimated three to five times the incidence compared to that of the general population. It is estimated that particularly in renal cell carcinoma (RCC), the relative risk increases. The aim of this study was to analyze the characteristics, risk factors, and prognosis of RCC following kidney transplantation.


Total number of 3,272 kidney recipients who underwent transplantation from April 1979 to December 2012 and patients who had RCC following kidney transplantation were retrospectively reviewed and analyzed.


We found that among 232 cases of posttransplant malignancies, 25 recipients were diagnosed with RCC. We have observed in our study that it took an average of 175.2±71.0 months to develop RCC after their first kidney transplantation. However, with longer follow up period, interval incidence of RCC increased. Fourteen patients (56%) were diagnosed with RCC 15 years after transplantation. We also found that with reference to the risk factor analysis for posttransplant RCC, the long-term follow-up period was the only independent risk factor. In our study, 21 patients with RCC were treated with radical nephrectomy. Of them, 16 patients survived, and four RCC-related deaths occurred. Furthermore, the patient survival rate of RCC recipients was lower than that of the nonmalignancy group despite the graft survival rate were not different.


We conclude that the incidence of RCC increased in a time-dependent manner following kidney transplantation. Therefore, we strongly recommend the procedure of regular-interval screening for the patients who are on compulsive long-term immunosuppression.

Keywords: Kidney transplantation; Renal cell carcinoma; Malignancy


Fig. 1
Interval incidence of renal cell carcinoma after kidney transplantation. Interval incidence of posttransplant renal cell carcinoma (RCC) increased time-dependently. Also, as the duration from starting dialysis increased, interval incidence of postdialysis RCC increased. Abbreviation: Post-Tx, posttransplant.
Click for larger image

Fig. 2
Renal cell carcinoma (RCC) occurrence according to the patients' survival.
Click for larger image

Fig. 3
(A, B) Graft and patient survival rates. Patient survival rates of the renal cell carcinoma (RCC) patients were worse than the patients without malignancy but graft survival rates were not different between the two groups.
Click for larger image


Table 1
Clinical manifestations of posttransplant renal cell carcinoma patients
Click for larger image

Table 2
Comparison between renal cell carcinoma and nonmalignancy patients
Click for larger image

Table 3
Risk factor analysis for posttransplant renal cell carcinoma
Click for larger image

1. Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009;69:2227–2243.
2. Ju MK, Joo DJ, Kim SJ, Huh KH, Kim MS, Jeon KO, et al. Chronologically different incidences of post-transplant malignancies in renal transplant recipients: single center experience. Transpl Int 2009;22:644–653.
3. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005;80 2 Suppl:S254–S264.
4. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4:905–913.
5. Leveridge M, Musquera M, Evans A, Cardella C, Pei Y, Jewett M, et al. Renal cell carcinoma in the native and allograft kidneys of renal transplant recipients. J Urol 2011;186:219–223.
6. Végsö G, Toronyi E, Hajdu M, Piros L, Görög D, Deák PA, et al. Renal cell carcinoma of the native kidney: a frequent tumor after kidney transplantation with favorable prognosis in case of early diagnosis. Transplant Proc 2011;43:1261–1263.
7. Zafar SY, Howell DN, Gockerman JP. Malignancy after solid organ transplantation: an overview. Oncologist 2008;13:769–778.
8. Doublet JD, Peraldi MN, Gattegno B, Thibault P, Sraer JD. Renal cell carcinoma of native kidneys: prospective study of 129 renal transplant patients. J Urol 1997;158:42–44.
9. Schwarz A, Vatandaslar S, Merkel S, Haller H. Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol 2007;2:750–756.
10. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1994;1994:99–109.
11. Ianhez LE, Lucon M, Nahas WC, Sabbaga E, Saldanha LB, Lucon AM, et al. Renal cell carcinoma in renal transplant patients. Urology 2007;69:462–464.
12. Heinz-Peer G, Schoder M, Rand T, Mayer G, Mostbeck GH. Prevalence of acquired cystic kidney disease and tumors in native kidneys of renal transplant recipients: a prospective US study. Radiology 1995;195:667–671.
13. Hoshida Y, Nakanishi H, Shin M, Satoh T, Hanai J, Aozasa K. Renal neoplasias in patients receiving dialysis and renal transplantation: clinico-pathological features and p53 gene mutations. Transplantation 1999;68:385–390.
14. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30:843–852.
15. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000;11 Suppl 15:S1–S86.
16. Goh A, Vathsala A. Native renal cysts and dialysis duration are risk factors for renal cell carcinoma in renal transplant recipients. Am J Transplant 2011;11:86–92.
17. Moudouni SM, Lakmichi A, Tligui M, Rafii A, Tchala K, Haab F, et al. Renal cell carcinoma of native kidney in renal transplant recipients. BJU Int 2006;98:298–302.
Similar articles

Experiences of renal transplants from donors with renal cell carcinoma after ex vivo partial nephrectomy

Clinical Characteristics of Focal Segmental Glomerulosclerosis Recurrence after Adult Renal Transplantation

Renal Cell Carcinoma in Kidney Transplant Recipients and Dialysis Patients

A Case of Squamous Cell Carcinoma in Nasal Cavity Treated with Conversion to Sirolimus in a Patient with Kidney Transplantation

Renal Cell Carcinoma in a Right Malrotated Kidney